100%
Skip to main content
Platform
GovTribe AI
AI-powered insights to accelerate your government contracting workflow.
MCP Server
Connect GovTribe to your AI tools.
Beacon
Find and connect with key government decision-makers.
Profiles
Federal Agencies
Federal Contract Vehicles
Federal Grant Programs
Major Defense Acquisition Programs
NAICS Categories
PSC Categories
States
Jurisdictions
NIGP Categories
UNSPSC Categories
Vendors
Enrichment By Clearbit
Reports
New Entrants
Funding Analysis
Vehicle Analysis
Groups
Capture
Pipelines
Pursuits
Alerts
Teaming
Data
Awards
Forecasts
Federal Opportunities
State & Local Opportunities
Files
Prime and Subcontractors
Activity
Search
Exports
Solutions
Use Case
Opportunity Identification
Capture Management
Competitive Intelligence
Teaming & Partner Identification
Proposal Management
Strategic Leadership
Go-to-Market Strategy
Industry
Federal Contractors
State & Local Contractors
Grant Seekers
Government Agencies
Research & Consulting
Pricing
More
About Us
Features
Get A Demo
Sign Up
Blog
User Guide
Data Model
GovTribe for Agents
Login
Contact sales
Try for free
Login
Contact sales
Try for free
All Federal Grant Awards
Project Grant R44NS084701
Award Date
9/30/14
Completion Date
8/31/24
Dollars Obligated
$3.6M
Overview
Activity
8
Transactions
8
Subawards
Similar Awards
Federal Agency
National Institute of Neurological Disorders and Stroke
Awardee
Creosalus Inc. (CBL5M5DKH3K7)
Federal Grant Program
93.853
Assistance Type
Project Grant
Place of Performance
Kentucky, USA
Update #1
Update #2
CATHETER FOR LARGE VOLUME INTRAPARENCHYMAL BRAIN THERAPIES
Posted 8/31/19
5
1
2
Mod #
Description
ReasonForModification
Federal Obligation
Date
Not listed
CATHETER FOR LARGE VOLUME INTRAPARENCHYMAL BRAIN THERAPIES - PROJECT ABSTRACT SIGNIFICANCE: NEURODEGENERATIVE AND MALIGNANT DISEASES ALONG WITH INJURY OF THE CENTRAL NERVOUS SYSTEM (CNS) AFFECT MILLIONS OF AMERICANS. THESE INJURIES AND DISEASES ARE OFTEN DEVASTATING AND DIFFICULT TO TREAT, AND EFFECTIVE DRUG DELIVERY REMAINS A SIGNIFICANT CHALLENGE. INFUSION OF DRUGS INTO THE BRAIN PARENCHYMA USING CONVECTION-ENHANCED DELIVERY (CED) ALLOWS DIRECT TREATMENT OF LESIONS, CIRCUMVENTING THE BLOOD BRAIN BARRIER. IN PARTICULAR, NEW TREATMENTS AND DISEASES CALL FOR LARGE REGIONS OF BRAIN TO BE SUBJECTED TO THERAPEUTIC DOSES. MULTIPLE CLINICAL TRIALS HAVE BEEN CONDUCTED USING CED TO DELIVER LARGE VOLUMES OF CHEMOTHERAPY AND IMMUNOTOXINS IN PATIENTS WITH GLIOMAS, BUT ACTUAL DRUG DELIVERY TO THE TUMOR HAS BEEN POOR FOR SEVERAL REASONS INCLUDING THE UNPREDICTABLE DISPERSION OF THE DRUG IN THE TISSUE. THESE ADVERSE EVENTS RESULT IN REDUCED EFFICACY AND INCREASED TOXICITY. TO OVERCOME THE LIMITATIONS ASSOCIATED WITH CONVENTIONAL CED CATHETERS IN HETEROGENEOUS TISSUE, THE APPLICANTS HAVE DEVELOPED A POROUS BRAIN INFUSION CATHETER (PBIC) FOR IMPROVED CNS DRUG DELIVERY. HYPOTHESIS: THE APPLICANT PROPOSES THAT PHASE II RESEARCH WILL CREATE A MULTI-CAPABILITY PBIC OPTIMIZED FOR SMALL TO LARGE VOLUME DISTRIBUTION AND SHORT TO LONG DURATIONS FOR MULTIPLE (SMALL TO LARGE) NEUROLOGICAL THERAPEUTICS. PHASE I RESULTS: APPLICANT HAS DEVELOPED A PBIC THAT MET AIM 1 DESIGN REQUIREMENTS AS DEMONSTRATED IN AIM 3 DESIGN VERIFICATION TESTING THAT HAS BEEN PASSED. IN AIM 2 IN VIVO PORCINE TESTING, THE PBIC DEMONSTRATED SUPERIOR LARGE VOLUME DISTRIBUTION (P=.03) COMPARED TO A STANDARD END PORT BRAIN INFUSION CATHETER, SUCH THAT THE PBIC IS EXPECTED TO BE USED IN BRAIN TUMOR HUMAN STUDIES BY A LEADING BRAIN TUMOR CENTER. SPECIFIC AIMS: WITH THE PROPOSED PHASE II PBIC RESEARCH, THE APPLICANTS EXPECT TO VERIFY AND VALIDATE AN OPTIMIZED PBIC DESIGN THAT PROVIDES BROAD CED PERFORMANCE CAPABILITIES TO CNS, INCLUDING CHRONIC DELIVERY TO ENHANCE COMMERCIALIZATION POTENTIAL. AIM 1: THE PBIC DESIGN WILL BE OPTIMIZED FOR SMALL TO LARGE VOLUME DISTRIBUTION FOR MULTIPLE THERAPEUTICS AND SHORT TO LONG DURATIONS. THE RESULTING PBIC DESIGN VERIFICATION AND PERFORMANCE CHARACTERIZATION TESTING, IN VITRO AND IN VIVO, WILL BE COMPLETED TO ALLOW FOR HUMAN USE AND PRODUCT APPROVALS. AIM 2: THE PBIC DESIGN WILL BE VALIDATED FOR HUMAN USE WITH THERAPEUTICS IN NON-CLINICAL MODELS, INCLUDING CHRONIC DELIVERY WITH THE INFUSION OF A CHEMOTHERAPEUTIC IN COMPANION DOG BRAIN TUMOR PATIENTS, DEMONSTRATING THE IND ENABLING CAPABILITIES OF THE PBIC FOR A BROAD RANGE OF THERAPEUTIC ADMINISTRATION PROTOCOLS. THESE AIM 2 STUDIES WILL REDUCE PBIC CLINICAL RISK AND ARE EXPECTED TO ACCELERATE CUSTOMER HUMAN STUDY ADOPTION.
($16k)
7/16/25
Not listed
CATHETER FOR LARGE VOLUME INTRAPARENCHYMAL BRAIN THERAPIES - PROJECT ABSTRACT SIGNIFICANCE: NEURODEGENERATIVE AND MALIGNANT DISEASES ALONG WITH INJURY OF THE CENTRAL NERVOUS SYSTEM (CNS) AFFECT MILLIONS OF AMERICANS. THESE INJURIES AND DISEASES ARE OFTEN DEVASTATING AND DIFFICULT TO TREAT, AND EFFECTIVE DRUG DELIVERY REMAINS A SIGNIFICANT CHALLENGE. INFUSION OF DRUGS INTO THE BRAIN PARENCHYMA USING CONVECTION-ENHANCED DELIVERY (CED) ALLOWS DIRECT TREATMENT OF LESIONS, CIRCUMVENTING THE BLOOD BRAIN BARRIER. IN PARTICULAR, NEW TREATMENTS AND DISEASES CALL FOR LARGE REGIONS OF BRAIN TO BE SUBJECTED TO THERAPEUTIC DOSES. MULTIPLE CLINICAL TRIALS HAVE BEEN CONDUCTED USING CED TO DELIVER LARGE VOLUMES OF CHEMOTHERAPY AND IMMUNOTOXINS IN PATIENTS WITH GLIOMAS, BUT ACTUAL DRUG DELIVERY TO THE TUMOR HAS BEEN POOR FOR SEVERAL REASONS INCLUDING THE UNPREDICTABLE DISPERSION OF THE DRUG IN THE TISSUE. THESE ADVERSE EVENTS RESULT IN REDUCED EFFICACY AND INCREASED TOXICITY. TO OVERCOME THE LIMITATIONS ASSOCIATED WITH CONVENTIONAL CED CATHETERS IN HETEROGENEOUS TISSUE, THE APPLICANTS HAVE DEVELOPED A POROUS BRAIN INFUSION CATHETER (PBIC) FOR IMPROVED CNS DRUG DELIVERY. HYPOTHESIS: THE APPLICANT PROPOSES THAT PHASE II RESEARCH WILL CREATE A MULTI-CAPABILITY PBIC OPTIMIZED FOR SMALL TO LARGE VOLUME DISTRIBUTION AND SHORT TO LONG DURATIONS FOR MULTIPLE (SMALL TO LARGE) NEUROLOGICAL THERAPEUTICS. PHASE I RESULTS: APPLICANT HAS DEVELOPED A PBIC THAT MET AIM 1 DESIGN REQUIREMENTS AS DEMONSTRATED IN AIM 3 DESIGN VERIFICATION TESTING THAT HAS BEEN PASSED. IN AIM 2 IN VIVO PORCINE TESTING, THE PBIC DEMONSTRATED SUPERIOR LARGE VOLUME DISTRIBUTION (P=.03) COMPARED TO A STANDARD END PORT BRAIN INFUSION CATHETER, SUCH THAT THE PBIC IS EXPECTED TO BE USED IN BRAIN TUMOR HUMAN STUDIES BY A LEADING BRAIN TUMOR CENTER. SPECIFIC AIMS: WITH THE PROPOSED PHASE II PBIC RESEARCH, THE APPLICANTS EXPECT TO VERIFY AND VALIDATE AN OPTIMIZED PBIC DESIGN THAT PROVIDES BROAD CED PERFORMANCE CAPABILITIES TO CNS, INCLUDING CHRONIC DELIVERY TO ENHANCE COMMERCIALIZATION POTENTIAL. AIM 1: THE PBIC DESIGN WILL BE OPTIMIZED FOR SMALL TO LARGE VOLUME DISTRIBUTION FOR MULTIPLE THERAPEUTICS AND SHORT TO LONG DURATIONS. THE RESULTING PBIC DESIGN VERIFICATION AND PERFORMANCE CHARACTERIZATION TESTING, IN VITRO AND IN VIVO, WILL BE COMPLETED TO ALLOW FOR HUMAN USE AND PRODUCT APPROVALS. AIM 2: THE PBIC DESIGN WILL BE VALIDATED FOR HUMAN USE WITH THERAPEUTICS IN NON-CLINICAL MODELS, INCLUDING CHRONIC DELIVERY WITH THE INFUSION OF A CHEMOTHERAPEUTIC IN COMPANION DOG BRAIN TUMOR PATIENTS, DEMONSTRATING THE IND ENABLING CAPABILITIES OF THE PBIC FOR A BROAD RANGE OF THERAPEUTIC ADMINISTRATION PROTOCOLS. THESE AIM 2 STUDIES WILL REDUCE PBIC CLINICAL RISK AND ARE EXPECTED TO ACCELERATE CUSTOMER HUMAN STUDY ADOPTION.
$0
7/15/25
Not listed
CATHETER FOR LARGE VOLUME INTRAPARENCHYMAL BRAIN THERAPIES - PROJECT ABSTRACT SIGNIFICANCE: NEURODEGENERATIVE AND MALIGNANT DISEASES ALONG WITH INJURY OF THE CENTRAL NERVOUS SYSTEM (CNS) AFFECT MILLIONS OF AMERICANS. THESE INJURIES AND DISEASES ARE OFTEN DEVASTATING AND DIFFICULT TO TREAT, AND EFFECTIVE DRUG DELIVERY REMAINS A SIGNIFICANT CHALLENGE. INFUSION OF DRUGS INTO THE BRAIN PARENCHYMA USING CONVECTION-ENHANCED DELIVERY (CED) ALLOWS DIRECT TREATMENT OF LESIONS, CIRCUMVENTING THE BLOOD BRAIN BARRIER. IN PARTICULAR, NEW TREATMENTS AND DISEASES CALL FOR LARGE REGIONS OF BRAIN TO BE SUBJECTED TO THERAPEUTIC DOSES. MULTIPLE CLINICAL TRIALS HAVE BEEN CONDUCTED USING CED TO DELIVER LARGE VOLUMES OF CHEMOTHERAPY AND IMMUNOTOXINS IN PATIENTS WITH GLIOMAS, BUT ACTUAL DRUG DELIVERY TO THE TUMOR HAS BEEN POOR FOR SEVERAL REASONS INCLUDING THE UNPREDICTABLE DISPERSION OF THE DRUG IN THE TISSUE. THESE ADVERSE EVENTS RESULT IN REDUCED EFFICACY AND INCREASED TOXICITY. TO OVERCOME THE LIMITATIONS ASSOCIATED WITH CONVENTIONAL CED CATHETERS IN HETEROGENEOUS TISSUE, THE APPLICANTS HAVE DEVELOPED A POROUS BRAIN INFUSION CATHETER (PBIC) FOR IMPROVED CNS DRUG DELIVERY. HYPOTHESIS: THE APPLICANT PROPOSES THAT PHASE II RESEARCH WILL CREATE A MULTI-CAPABILITY PBIC OPTIMIZED FOR SMALL TO LARGE VOLUME DISTRIBUTION AND SHORT TO LONG DURATIONS FOR MULTIPLE (SMALL TO LARGE) NEUROLOGICAL THERAPEUTICS. PHASE I RESULTS: APPLICANT HAS DEVELOPED A PBIC THAT MET AIM 1 DESIGN REQUIREMENTS AS DEMONSTRATED IN AIM 3 DESIGN VERIFICATION TESTING THAT HAS BEEN PASSED. IN AIM 2 IN VIVO PORCINE TESTING, THE PBIC DEMONSTRATED SUPERIOR LARGE VOLUME DISTRIBUTION (P=.03) COMPARED TO A STANDARD END PORT BRAIN INFUSION CATHETER, SUCH THAT THE PBIC IS EXPECTED TO BE USED IN BRAIN TUMOR HUMAN STUDIES BY A LEADING BRAIN TUMOR CENTER. SPECIFIC AIMS: WITH THE PROPOSED PHASE II PBIC RESEARCH, THE APPLICANTS EXPECT TO VERIFY AND VALIDATE AN OPTIMIZED PBIC DESIGN THAT PROVIDES BROAD CED PERFORMANCE CAPABILITIES TO CNS, INCLUDING CHRONIC DELIVERY TO ENHANCE COMMERCIALIZATION POTENTIAL. AIM 1: THE PBIC DESIGN WILL BE OPTIMIZED FOR SMALL TO LARGE VOLUME DISTRIBUTION FOR MULTIPLE THERAPEUTICS AND SHORT TO LONG DURATIONS. THE RESULTING PBIC DESIGN VERIFICATION AND PERFORMANCE CHARACTERIZATION TESTING, IN VITRO AND IN VIVO, WILL BE COMPLETED TO ALLOW FOR HUMAN USE AND PRODUCT APPROVALS. AIM 2: THE PBIC DESIGN WILL BE VALIDATED FOR HUMAN USE WITH THERAPEUTICS IN NON-CLINICAL MODELS, INCLUDING CHRONIC DELIVERY WITH THE INFUSION OF A CHEMOTHERAPEUTIC IN COMPANION DOG BRAIN TUMOR PATIENTS, DEMONSTRATING THE IND ENABLING CAPABILITIES OF THE PBIC FOR A BROAD RANGE OF THERAPEUTIC ADMINISTRATION PROTOCOLS. THESE AIM 2 STUDIES WILL REDUCE PBIC CLINICAL RISK AND ARE EXPECTED TO ACCELERATE CUSTOMER HUMAN STUDY ADOPTION.
$0
7/15/25
Not listed
CATHETER FOR LARGE VOLUME INTRAPARENCHYMAL BRAIN THERAPIES - PROJECT ABSTRACT SIGNIFICANCE: NEURODEGENERATIVE AND MALIGNANT DISEASES ALONG WITH INJURY OF THE CENTRAL NERVOUS SYSTEM (CNS) AFFECT MILLIONS OF AMERICANS. THESE INJURIES AND DISEASES ARE OFTEN DEVASTATING AND DIFFICULT TO TREAT, AND EFFECTIVE DRUG DELIVERY REMAINS A SIGNIFICANT CHALLENGE. INFUSION OF DRUGS INTO THE BRAIN PARENCHYMA USING CONVECTION-ENHANCED DELIVERY (CED) ALLOWS DIRECT TREATMENT OF LESIONS, CIRCUMVENTING THE BLOOD BRAIN BARRIER. IN PARTICULAR, NEW TREATMENTS AND DISEASES CALL FOR LARGE REGIONS OF BRAIN TO BE SUBJECTED TO THERAPEUTIC DOSES. MULTIPLE CLINICAL TRIALS HAVE BEEN CONDUCTED USING CED TO DELIVER LARGE VOLUMES OF CHEMOTHERAPY AND IMMUNOTOXINS IN PATIENTS WITH GLIOMAS, BUT ACTUAL DRUG DELIVERY TO THE TUMOR HAS BEEN POOR FOR SEVERAL REASONS INCLUDING THE UNPREDICTABLE DISPERSION OF THE DRUG IN THE TISSUE. THESE ADVERSE EVENTS RESULT IN REDUCED EFFICACY AND INCREASED TOXICITY. TO OVERCOME THE LIMITATIONS ASSOCIATED WITH CONVENTIONAL CED CATHETERS IN HETEROGENEOUS TISSUE, THE APPLICANTS HAVE DEVELOPED A POROUS BRAIN INFUSION CATHETER (PBIC) FOR IMPROVED CNS DRUG DELIVERY. HYPOTHESIS: THE APPLICANT PROPOSES THAT PHASE II RESEARCH WILL CREATE A MULTI-CAPABILITY PBIC OPTIMIZED FOR SMALL TO LARGE VOLUME DISTRIBUTION AND SHORT TO LONG DURATIONS FOR MULTIPLE (SMALL TO LARGE) NEUROLOGICAL THERAPEUTICS. PHASE I RESULTS: APPLICANT HAS DEVELOPED A PBIC THAT MET AIM 1 DESIGN REQUIREMENTS AS DEMONSTRATED IN AIM 3 DESIGN VERIFICATION TESTING THAT HAS BEEN PASSED. IN AIM 2 IN VIVO PORCINE TESTING, THE PBIC DEMONSTRATED SUPERIOR LARGE VOLUME DISTRIBUTION (P=.03) COMPARED TO A STANDARD END PORT BRAIN INFUSION CATHETER, SUCH THAT THE PBIC IS EXPECTED TO BE USED IN BRAIN TUMOR HUMAN STUDIES BY A LEADING BRAIN TUMOR CENTER. SPECIFIC AIMS: WITH THE PROPOSED PHASE II PBIC RESEARCH, THE APPLICANTS EXPECT TO VERIFY AND VALIDATE AN OPTIMIZED PBIC DESIGN THAT PROVIDES BROAD CED PERFORMANCE CAPABILITIES TO CNS, INCLUDING CHRONIC DELIVERY TO ENHANCE COMMERCIALIZATION POTENTIAL. AIM 1: THE PBIC DESIGN WILL BE OPTIMIZED FOR SMALL TO LARGE VOLUME DISTRIBUTION FOR MULTIPLE THERAPEUTICS AND SHORT TO LONG DURATIONS. THE RESULTING PBIC DESIGN VERIFICATION AND PERFORMANCE CHARACTERIZATION TESTING, IN VITRO AND IN VIVO, WILL BE COMPLETED TO ALLOW FOR HUMAN USE AND PRODUCT APPROVALS. AIM 2: THE PBIC DESIGN WILL BE VALIDATED FOR HUMAN USE WITH THERAPEUTICS IN NON-CLINICAL MODELS, INCLUDING CHRONIC DELIVERY WITH THE INFUSION OF A CHEMOTHERAPEUTIC IN COMPANION DOG BRAIN TUMOR PATIENTS, DEMONSTRATING THE IND ENABLING CAPABILITIES OF THE PBIC FOR A BROAD RANGE OF THERAPEUTIC ADMINISTRATION PROTOCOLS. THESE AIM 2 STUDIES WILL REDUCE PBIC CLINICAL RISK AND ARE EXPECTED TO ACCELERATE CUSTOMER HUMAN STUDY ADOPTION.
$0
9/13/23
Not listed
CATHETER FOR LARGE VOLUME INTRAPARENCHYMAL BRAIN THERAPIES - PROJECT ABSTRACT SIGNIFICANCE: NEURODEGENERATIVE AND MALIGNANT DISEASES ALONG WITH INJURY OF THE CENTRAL NERVOUS SYSTEM (CNS) AFFECT MILLIONS OF AMERICANS. THESE INJURIES AND DISEASES ARE OFTEN DEVASTATING AND DIFFICULT TO TREAT, AND EFFECTIVE DRUG DELIVERY REMAINS A SIGNIFICANT CHALLENGE. INFUSION OF DRUGS INTO THE BRAIN PARENCHYMA USING CONVECTION-ENHANCED DELIVERY (CED) ALLOWS DIRECT TREATMENT OF LESIONS, CIRCUMVENTING THE BLOOD BRAIN BARRIER. IN PARTICULAR, NEW TREATMENTS AND DISEASES CALL FOR LARGE REGIONS OF BRAIN TO BE SUBJECTED TO THERAPEUTIC DOSES. MULTIPLE CLINICAL TRIALS HAVE BEEN CONDUCTED USING CED TO DELIVER LARGE VOLUMES OF CHEMOTHERAPY AND IMMUNOTOXINS IN PATIENTS WITH GLIOMAS, BUT ACTUAL DRUG DELIVERY TO THE TUMOR HAS BEEN POOR FOR SEVERAL REASONS INCLUDING THE UNPREDICTABLE DISPERSION OF THE DRUG IN THE TISSUE. THESE ADVERSE EVENTS RESULT IN REDUCED EFFICACY AND INCREASED TOXICITY. TO OVERCOME THE LIMITATIONS ASSOCIATED WITH CONVENTIONAL CED CATHETERS IN HETEROGENEOUS TISSUE, THE APPLICANTS HAVE DEVELOPED A POROUS BRAIN INFUSION CATHETER (PBIC) FOR IMPROVED CNS DRUG DELIVERY. HYPOTHESIS: THE APPLICANT PROPOSES THAT PHASE II RESEARCH WILL CREATE A MULTI-CAPABILITY PBIC OPTIMIZED FOR SMALL TO LARGE VOLUME DISTRIBUTION AND SHORT TO LONG DURATIONS FOR MULTIPLE (SMALL TO LARGE) NEUROLOGICAL THERAPEUTICS. PHASE I RESULTS: APPLICANT HAS DEVELOPED A PBIC THAT MET AIM 1 DESIGN REQUIREMENTS AS DEMONSTRATED IN AIM 3 DESIGN VERIFICATION TESTING THAT HAS BEEN PASSED. IN AIM 2 IN VIVO PORCINE TESTING, THE PBIC DEMONSTRATED SUPERIOR LARGE VOLUME DISTRIBUTION (P=.03) COMPARED TO A STANDARD END PORT BRAIN INFUSION CATHETER, SUCH THAT THE PBIC IS EXPECTED TO BE USED IN BRAIN TUMOR HUMAN STUDIES BY A LEADING BRAIN TUMOR CENTER. SPECIFIC AIMS: WITH THE PROPOSED PHASE II PBIC RESEARCH, THE APPLICANTS EXPECT TO VERIFY AND VALIDATE AN OPTIMIZED PBIC DESIGN THAT PROVIDES BROAD CED PERFORMANCE CAPABILITIES TO CNS, INCLUDING CHRONIC DELIVERY TO ENHANCE COMMERCIALIZATION POTENTIAL. AIM 1: THE PBIC DESIGN WILL BE OPTIMIZED FOR SMALL TO LARGE VOLUME DISTRIBUTION FOR MULTIPLE THERAPEUTICS AND SHORT TO LONG DURATIONS. THE RESULTING PBIC DESIGN VERIFICATION AND PERFORMANCE CHARACTERIZATION TESTING, IN VITRO AND IN VIVO, WILL BE COMPLETED TO ALLOW FOR HUMAN USE AND PRODUCT APPROVALS. AIM 2: THE PBIC DESIGN WILL BE VALIDATED FOR HUMAN USE WITH THERAPEUTICS IN NON-CLINICAL MODELS, INCLUDING CHRONIC DELIVERY WITH THE INFUSION OF A CHEMOTHERAPEUTIC IN COMPANION DOG BRAIN TUMOR PATIENTS, DEMONSTRATING THE IND ENABLING CAPABILITIES OF THE PBIC FOR A BROAD RANGE OF THERAPEUTIC ADMINISTRATION PROTOCOLS. THESE AIM 2 STUDIES WILL REDUCE PBIC CLINICAL RISK AND ARE EXPECTED TO ACCELERATE CUSTOMER HUMAN STUDY ADOPTION.
$304.9k
9/1/21